{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:29:50Z","timestamp":1788967790751,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Live-attenuated zoster vaccine (LZV) and adjuvanted recombinant zoster vaccine (RZV) have been approved for use in China. This study aimed to evaluate and compare the cost-effectiveness of these two herpes zoster (HZ) vaccination strategies in a birth cohort of individuals aged 50\u202fyears.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cost-effectiveness of RZV and LZV was compared to no vaccination strategy using a lifetime Markov model from a societal perspective. Model parameters were obtained from up-to-date published literature and statistical data. The costs associated with vaccination and medical treatment, quality-adjusted life years (QALYs), the number of herpes zoster and related complication cases averted, and the incremental cost-effectiveness ratio (ICER) were calculated. Sensitivity analyses were performed to assess the robustness of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to the no-vaccination strategy, the RZV strategy was estimated to prevent 4,126 HZ cases and 772 postherpetic neuralgia (PHN) cases, while the LZV strategy was estimated to avert 2,355 HZ cases and 467 PHN cases. The ICER was estimated at 711.46 US $\/QALY and 914.62 US $\/QALY for the RZV and LZV strategies, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HZ vaccination could provide significant health benefits at a reasonable cost. RZV was predicted to be more cost-effective than LZV.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1401930","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:30:51Z","timestamp":1747114251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50\u202fyears in Zhejiang province, China"],"prefix":"10.3389","volume":"13","author":[{"given":"Fuxing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/14787210.2020.1792290","article-title":"A systematic literature review to assess the burden of herpes zoster disease in China","volume":"19","author":"Yin","year":"2021","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12879-017-2198-y","article-title":"Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1080\/21645515.2018.1489193","article-title":"A retrospective survey on herpes zoster disease burden and characteristics in Beijing","volume":"14","author":"Lu","year":"2018","journal-title":"China Hum Vaccin Immunother"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1080\/21645515.2021.1960137","article-title":"Low willingness to vaccinate against herpes zoster in a Chinese metropolis","volume":"17","author":"Lu","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: a systematic review","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine"},{"key":"ref9","unstructured":"2022"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1080\/21645515.2018.1504523","article-title":"Routine vaccination coverage of children aged 1-7 years in Zhejiang province, China","volume":"14","author":"Hu","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2228169","DOI":"10.1080\/21645515.2023.2228169","article-title":"The incidence of herpes zoster in China: a meta-analysis and evidence quality assessment","volume":"19","author":"Zhang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jinf.2020.12.013","article-title":"Incidence and disease burden of herpes zoster in the population aged \u226550 years in China: data from an integrated health care network","volume":"82","author":"Sun","year":"2021","journal-title":"J Infect"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","article-title":"Cost-effectiveness analysis update of the Adjuvanted recombinant zoster vaccine in Japanese older adults","volume":"12","author":"Teng","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2340\/00015555-0729","article-title":"Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006","volume":"89","author":"Jih","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.19914\/j.cjvi.2019.04.016","article-title":"Epidemiological characteristics of herpes zoster in urban areas of Yichang city during 2016-2017 based on the Yichang big data platform for health management","volume":"25","author":"Jiang","year":"2019","journal-title":"Chin J Vaccines Immun"},{"key":"ref16","unstructured":"Walker\n              DG\n            \n            \n              Hutubessy\n              R\n            \n            \n              Beutels\n              P\n            \n          \n          \n          2023"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0152660","DOI":"10.1371\/journal.pone.0152660","article-title":"Disease burden due to herpes zoster among population aged \u2265 50 years old in China: a community based retrospective survey","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/CEOR.S203920","article-title":"Patient and economic burdens of postherpetic neuralgia in China","volume":"11","author":"Yu","year":"2019","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"ref19","volume-title":"China health statistical yearbook","year":"2021"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/ane.13485","article-title":"Direct economic burden of patients with tuberculous meningitis in western China","volume":"144","author":"Ma","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.puhe.2015.10.009","article-title":"Social networks and health-related quality of life among Chinese old adults in urban areas: results from 4th National Household Health Survey","volume":"131","author":"Lei","year":"2016","journal-title":"Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s12325-021-01717-7","article-title":"Economic burden and impact on quality of life of herpes zoster in Spanish adults aged 50 years or older: a prospective cohort study","volume":"38","author":"Diez-Domingo","year":"2021","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcma.2017.06.024","article-title":"Cost-effectiveness analysis of endoscopic tympanoplasty versus microscopic tympanoplasty for chronic otitis media in Taiwan","volume":"81","author":"Tseng","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"647725","DOI":"10.3389\/fpubh.2021.647725","article-title":"Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine program for the elderly aged 60 years or older in Shanghai, China","volume":"9","author":"Sun","year":"2021","journal-title":"Front Public Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.agecon.2003.11.006","article-title":"World health report 2002: reducing risks, promoting healthy life: World Health Organization, Geneva, 2002, 250 pages, US$ 13.50, ISBN 9-2415-6207-2","volume":"30","author":"Mutangadura","year":"2004","journal-title":"Agric Econ"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an Adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-018-1213-5","article-title":"Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines","volume":"16","author":"de Boer","year":"2018","journal-title":"BMC Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live","volume":"15","author":"Curran","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","article-title":"Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study","volume":"191","author":"Drolet","year":"2019","journal-title":"CMAJ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"Melegaro","year":"2018","journal-title":"BMC Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1086\/591975","article-title":"Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1401930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:30:53Z","timestamp":1747114253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1401930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":31,"alternative-id":["10.3389\/fpubh.2025.1401930"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1401930","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1401930"}}